Park A-La, Jez Oliver, Kilian Reinhold, Charles Ashleigh, Kalha Jasmine, Korde Palak, Lachmann Max, Mahlke Candelaria, Moran Galia, Nakku Juliet, Ngakongwa F, Niwemuhwezi Jackline, Nixdorf Rebecca, Ryan Grace, Shamba Donat, Slade Mike, Waldmann T
Care Policy and Evaluation Centre, Department of Health Policy, London School of Economics and Political Science, London, UK.
Department of Psychiatry and Psychotherapy II, University of Ulm and BKH Günzburg, Günzburg, Germany.
Epidemiol Psychiatr Sci. 2025 Jul 16;34:e40. doi: 10.1017/S2045796025100140.
AIMS: The aim of the article is to undertake the first economic analysis exploring the costs of illness (COIs) and factors affecting COIs in people living with mental disorders using individual patient-level data across five countries with different national income levels. This is done by investigating diagnosis-related and sociodemographic factors for country-specific medical and psychosocial service use in these high, lower-middle and low-income countries. METHODS: Using data from the Using Peer Support In Developing Empowering Mental Health Services (UPSIDES) study, a pragmatic randomized controlled trial, costs for medical and psychosocial services have been estimated over 6 months in 615 people with severe mental illness from Germany ( = 171), Uganda ( = 138), Tanzania ( = 110), India ( = 93) and Israel ( = 103). The primary economic analysis included (1) total COI expressed in 2021 international dollars and (2) proportional cost-type expenditures. Generalized linear regression models were also used to estimate the impact of psychiatric diagnosis, social disability, age and gender on the total COI. RESULTS: Of the 615 participants (mean [SD] age 38.3 [11.2] years; 335 [54.5%] women), the total 6-month COI ranged from $311.48 [±547.47] in Tanzania to $10,493.19 [±13324.10] in Germany. High-income Germany and low-income Uganda both concentrated >70% of COIs on inpatient care. High-income Israel had the most balanced COI, with the lowest mean share (15.40%) on inpatient care, compared with community (35.12%) and primary care (33.01%). Female gender was associated with lower COI ( = 0.215; = 0.000) in Tanzania, while in India diagnosis of depression was associated with lower costs than schizophrenia ( = 0.363; = 0.017). Health of the Nation Outcome Scale scores (social disability) were not significantly associated with COIs in any country. In Tanzania, the total mean COI increased by 3.6% for every additional year of age. Compared to Germany, mean COIs were significantly lower by 90%, 99% and 86% in Uganda, Tanzania and India, respectively, and by 50% in Israel, although this difference was not significant. CONCLUSIONS: National income is correlated with the total COI in people living with mental disorders but is a poor predictor of the sector-specific distribution of these expenditures.
目的:本文旨在进行首次经济分析,利用来自五个不同国民收入水平国家的个体患者层面数据,探究精神障碍患者的疾病成本(COIs)以及影响疾病成本的因素。通过调查这些高收入、中低收入和低收入国家中与诊断相关的因素以及社会人口学因素,以了解特定国家医疗和心理社会服务的使用情况。 方法:利用“在发展中增强心理健康服务中使用同伴支持”(UPSIDES)研究的数据,这是一项务实的随机对照试验,对来自德国(n = 171)、乌干达(n = 138)、坦桑尼亚(n = 110)、印度(n = 93)和以色列(n = 103)的615名严重精神疾病患者在6个月内的医疗和心理社会服务成本进行了估算。主要经济分析包括:(1)以2021年国际美元表示的总疾病成本;(2)成本类型的比例支出。还使用广义线性回归模型来估计精神疾病诊断、社会残疾、年龄和性别对总疾病成本的影响。 结果:在615名参与者中(平均[标准差]年龄38.3[11.2]岁;335名[54.5%]为女性),6个月的总疾病成本范围从坦桑尼亚的311.48美元[±547.47]到德国的10493.19美元[±13324.10]。高收入的德国和低收入的乌干达都将超过70%的疾病成本集中在住院治疗上。高收入的以色列疾病成本分布最为均衡,住院治疗的平均份额最低(15.40%),而社区治疗(35.12%)和初级保健(33.01%)的份额相对较高。在坦桑尼亚,女性与较低的疾病成本相关(β = 0.215;p = 0.000),而在印度,抑郁症诊断的成本低于精神分裂症(β = 0.363;p = 0.017)。在任何国家,国民健康结果量表得分(社会残疾)与疾病成本均无显著关联。在坦桑尼亚,年龄每增加一岁,总平均疾病成本增加3.6%。与德国相比,乌干达、坦桑尼亚和印度的平均疾病成本分别显著低90%、99%和86%,以色列低50%,尽管这种差异不显著。 结论:国民收入与精神障碍患者的总疾病成本相关,但对于这些支出在不同部门的分布情况预测能力较差。
Health Technol Assess. 2001
Cochrane Database Syst Rev. 2016-6-22
J Ment Health Policy Econ. 2025-6-1
Cochrane Database Syst Rev. 2010-10-6
Cochrane Database Syst Rev. 2013-3-28
Asian J Psychiatr. 2024-12
Lancet Reg Health Southeast Asia. 2023-10-9
Int J Ment Health Syst. 2023-3-28
EClinicalMedicine. 2022-9-28
Int J Environ Res Public Health. 2022-6-2
Soc Psychiatry Psychiatr Epidemiol. 2023-6